Comparison 2.

Artemisinin treatment regimen: PQ versus no PQ

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with gametocytes (microscopy)	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Day 4	4	971	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.95, 1.05]
1.2 Day 8	5	1071	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.08, 0.54]
1.3 Day 15	4	995	Risk Ratio (M-H, Random, 95% CI)	0.09 [0.04, 0.19]
1.4 Day 22	3	858	Risk Ratio (M-H, Random, 95% CI)	0.10 [0.03, 0.32]
1.5 Day 29	4	945	Risk Ratio (M-H, Random, 95% CI)	0.17 [0.04, 0.72]
1.6 Day 36	3	838	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.01, 4.32]
1.7 Day 43	4	917	Risk Ratio (M-H, Random, 95% CI)	0.41 [0.04, 3.89]
2 Participants with gametocytes (PCR)	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Day 8	3	627	Risk Ratio (M-H, Random, 95% CI)	0.42 [0.26, 0.69]
2.2 Day 15	3	609	Risk Ratio (M-H, Random, 95% CI)	0.27 [0.11, 0.70]
2.3 Day 29	1	90	Risk Ratio (M-H, Random, 95% CI)	0.23 [0.08, 0.62]
2.4 Day 43	1	79	Risk Ratio (M-H, Random, 95% CI)	0.44 [0.17, 1.16]
3 Participants with asexual parasites	5		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Day 8	1	94	Risk Ratio (M-H, Fixed, 95% CI)	1.28 [0.30, 5.40]
3.2 Day 15	2	198	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.23, 4.15]
3.3 Day 29	3	747	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.33, 0.88]
3.4 Day 43	2	178	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.59, 1.81]
4 Asexual parasite clearance time (hrs)	1	50	Mean Difference (IV, Fixed, 95% CI)	-6.0 [-16.31, 4.31]
5 Haemoglobin concentration	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 Day 8	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Day 15	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.3 Day 29	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.4 Day 43	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 % change in haemoglobin concentration	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.1 Day 8	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 Day 15	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.3 Day 29	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.4 Day 43	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Other adverse effects	2		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
7.1 Headache	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 Fatigue	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.3 Nausea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.4 Vomiting	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.5 Abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.6 Diarrhea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.7 Pruritis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.8 Paresthesia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.9 Unspecified	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 By dose: Participants with gametocytes at day 8 (microscopy or PCR)	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
8.1 < 0.4 mg/kg PQ per day	1	223	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.44, 1.02]
8.2 ≥ 0.4 to < 0.6 mg/kg PQ per day	1	219	Risk Ratio (M-H, Fixed, 95% CI)	0.30 [0.16, 0.56]
8.3 ≥ 0.6 mg/kg PQ per day	7	1380	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.22, 0.37]
9 By schedule: Participants with gametocytes at day 8 (microscopy or PCR)	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
9.1 Single dose day 1 or 2	2	843	Risk Ratio (M-H, Fixed, 95% CI)	0.13 [0.07, 0.22]
9.2 Single dose day 3 or 4	5	748	Risk Ratio (M-H, Fixed, 95% CI)	0.47 [0.37, 0.59]
9.3 Multiple dose days 1 to 7	0	0	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]